Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth third quarter

This article was originally published in The Tan Sheet

Executive Summary

Wyeth Consumer Healthcare's recent divestiture of theSolgar supplement business contributed to a 4.7% dip in domestic revenues for the third quarter, the firm reported during an earnings call Oct. 21.Wyeth closed the sale of its Solgar business to NBTY for $115 mil. on Aug. 1. Domestic sales for the division during the quarter closed at $382.5 mil., down from $401.5 mil. during the third quarter of 2004. Losses due to Solgar were partially offset by gains in worldwide Centrum revenues, up 14% to $150 mil. for the third quarter, the company said. Growth during the first nine months for the division was driven by a global increase in Robitussin, Caltrate and Advil sales. When excluding the impact of foreign exchange, total worldwide consumer net revenue decreased by 4% for the third quarter, Wyeth stated...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS098766

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel